Log In
BCIQ
Print this Print this
 

ribaxamase (SYN-004) (formerly P3A)

  Manage Alerts
Collapse Summary General Information
Company Synthetic Biologics Inc.
DescriptionSecond-generation, oral beta lactamase (LACTB) that binds with and neutralizes IV beta-lactam antibiotics in the gut
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase II
Standard IndicationClostridium
Indication DetailsPrevent Clostridium difficile infection (CDI) when co-administered with IV beta-lactam antibiotics; Prevent Clostridium difficile infection (CDI), C. difficile associated diarrhea (CDAD) and antibiotic-associated diarrhea (AAD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1.4M

$0.2M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/19/2012

$1.4M

$0.2M

Undisclosed

Get a free BioCentury trial today